Dr. Joan Fallon, founder and chief executive officer of Curemark, has made it her lifelong mission to improve healthcare and quality of life for children, focusing her company on the development of novel therapies for the treatment of neurological disorders. Currently, Curemark is enrolling children three to eight in a Phase 3 clinical trial for autism, in addition to having a Phase 3-ready clinical-stage research program for ADHD and preclinical programs for addiction, schizophrenia, and Parkinson’s.
Born in New York, Joan served on the ADA board for the building of the new Yankee Stadium. She holds appointments as a senior advisor to the Henry Crown Fellows at the Aspen Institute and as a distinguished fellow at the Athena Center for Leadership Studies at Barnard College. She is also a member of the board of Franklin & Marshall College, her alma mater, and currently holds 120 patents worldwide. She was recently named EY’s Entrepreneur of the Year 2017 New York award winner in healthcare.
Joan is a fifth-generation Irish American and has traced her father’s family roots to County Galway. She believes that “strength, fortitude, patience, and perseverance,” qualities she draws from her Irish heritage, are necessary to lead Curemark to a bright future. She currently resides in White Plains, New York.